Table 4.
Univariate Cox analysis of the risk factors of overall survival in the 91 patients with pulmonary adenocarcinoma
| n (%) | mOS, months (95% CI) | HR (95% CI) | P-value | c-Statistics | |
|---|---|---|---|---|---|
| Overall | 91 | 80 (72.4–87.6) | NA | ||
| Sex | 0.61 (0.34–1.11) | 0.099 | 0.559 | ||
| Male | 43 (47.2) | 74 (61.0–97.0) | |||
| Female | 48 (52.8) | 88 (75.4–100.6) | |||
| Age, years | 1.47 (0.81–2.66) | 0.207 | 0.547 | ||
| ≤60 | 50 (54.9) | 88 (74.7–101.3) | |||
| >60 | 41 (45.1) | 74 (56.7–91.3) | |||
| Smoking status | 0.82 (0.41–1.67) | 0.585 | 0.516 | ||
| Nonsmoking | 66 (72.5) | 78 (68.2–87.8) | |||
| Smoking (current/ever) | 25 (27.5) | 81 (60.2–101.8) | |||
| Tumor size | 3.21 (1.75–5.87) | 1.65*10−4 | 0.643 | ||
| ≤2.5 cm | 53 (58.2) | 101+ | |||
| >2.5 cm | 38 (41.8) | 61 (51.5–65.5) | |||
| TNM stage | 3.14 (1.72–5.74) | 1.89*10−4 | 0.640 | ||
| Ia | 53 (58.2) | 101+ | |||
| Ib | 38 (41.8) | 61 (51.5–70.5) | |||
| IASLC/ATS/ERS classification | 3.06 (1.98–4.73) | 5.33*10−7 | 0.704 | ||
| Low | 24 (26.4) | 101+ | |||
| Intermediate | 41 (45.0) | 79 (71.9–86.1) | |||
| High | 26 (28.6) | 48 (34.3–61.7) | |||
| RS10 | 3.42 (1.74–6.72) | 3.81*10−4 | 0.587 | ||
| Low | 75 (82.4) | 81 (67.2–94.8) | |||
| High | 16 (17.6) | 51 (38.2–63.8) | |||
| RS2 | 3.2 (1.74–6.07) | 2.11*10−4 | 0.644 | ||
| Low | 47 (51.6) | 101+ | |||
| High | 44 (48.4) | 61 (56.8–65.2) |
Note:
*
P<0.05.
Abbreviations: ATS, American Thoracic Society; CI, confidence interval; ERS, European Respiratory Society; HR, hazard ratio; IASLC, International Association for the Study of Lung Cancer; mOS, median overall survival; NA, not available; RS2, risk score of two-gene signature; RS10, risk score of ten-gene signature.